drugset / Trial / NCT00784875

An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia

NCT00784875

Phase 2 Completed 643 enrolled Eli Lilly and Company
RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this study is to compare an investigational drug (LY2624803) with placebo and with zolpidem in the treatment of outpatients with chronic insomnia.

Timeline

Start
2008-10
Primary completion
2010-02
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2624803 Small molecule 1 mg Oral
Subject LY2624803 Small molecule 3 mg Oral
Subject Zolpidem Small molecule 5 mg Oral
Subject Zolpidem Small molecule 10 mg Oral

Indications